Articles published by Pint Pharma
Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.
July 09, 2024
From
Pint Pharma
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.